卵巢肿瘤患者血清CA125的检测及其意义

目的：探讨CA125检测在卵巢肿瘤患者中的临床意义。方法：应用免疫放射分析法（IRMA）测定75例恶性卵巢肿瘤（包括上皮性恶性卵巢肿瘤62例．非上皮性恶性卵巢肿瘤13例）、19例子宫内膜异位症、13例盆腔结缔组织炎、96例良性上皮性卵巢肿瘤、13例交界性卵巢肿瘤及52例健康女性的血清CA125值．并结合其临床表现作统计学分析。结果：恶性上皮性卵巢肿瘤患者血清CA125值明显高于良性卵巢肿瘤、交界性卵巢肿瘤和非上皮性恶性卵巢肿瘤患者．差异有显著性（P〈0.01）；但与子宫内膜异位症、盆腔结缔组织炎患者血清CA125值比较差异无显著性（P〉0.05）；血清CA125的表达与上皮性恶性卵巢肿瘤的临床分期、化疗疗效密切相关（P〈0．01）。结论，血清CA125作为卵巢肿瘤标记物的重要指标，应在其诊断及治疗中常规检测。

Detection of serum CA125 in patients with ovarian tumors

Objective: To investigate the change of serum CA_(125) level and its clinical significance in patients with ovarian tumors. Methods: Serum CA_(125) level was determined by immunoradiometry in 75 patients with malignant ovarian tumors, 96 benign ovarian tumors, 13 borderline ovarian tumors, 19 endometriosis, 13 pelvic inflammation, and 52 healthy women. Results: Serum CA_(125) content in patients with epithelial ovarian cancers was significantly higher than those with non-epithelial ovarian cancers, benign ovarian tumors, and borderline ovarian tumors (P<0.01), but it was not superior to that in patients with endometriosis and pelvic inflammation (P>0.05). CA_(125) level was correlated with clinical staging and chemotherapeutic efficacy in epithelial ovarian cancers (P<0.01). Conclusion: Serum CA_(125) maybe a marker for ovarian cancer.